On June 11, 2025, Telomir Pharmaceuticals reported preclinical results showing that its drug Telomir-1 significantly improves neurological and organ functions in an animal model of Wilson’s disease, reducing copper accumulation and clinical symptoms by up to 50%. The company aims to advance Telomir-1 towards human trials in 2026.